Tick tock Wednesday, October 2, in the big theater

Tick tock Wednesday, October 2, in the big theater seating courtroom in Washington, DC. According to Mr. Sensitivity, who some here know of, the company's major argument should be all about the Tangential Exception Rule and Doctrine of Prosecution History Estoppel. It's all about the efficacy of the company's patents. Two cases involving three appeals came down in the last several weeks from the same court favorable to DECN. Federal Circuit 2018-1590, 2018-1629 and Federal Circuit 2018-2128. If someone cares, pay closer attention to the latter appeal, 2018-2128.

DECN wins and everything changes and not just damages from patent infringement, but damages from J&J strong-arming DECN customers and potential customers, threatening to sue customers who bought DECN GenUltimate products, J&J's use of protected materials gathered and under seal from other cases involving J&J and DECN customers (again) where each of these potential customers, primarily independent pharmacies were sent 30 page letters outlining potential upcoming litigation, and finally the words and actions of J&J's Chairman who has made DECN's case for them.

I do not believe Mr. Berman, DECN CEO, wants to litigate against J&J forever. The hearing on October 2, will determine what a settlement will look like.

Do not believe what message board posters masquerading as courtroom experts say here. Stock traders are not litigation experts, or for that matter experts at much of anything. Follow the odds makers, the litigation stock players. Litigation players own, by Sensi's count, almost 36 million DECN shares. And those are people Sensi knows or knows of. It could be higher. It is looking good. All IMO.